This project will use the transgenic """"""""XenoMouse"""""""" system, developed by Abgenix, to isolate novel human monoclonal antibodies against HIV-1 which possess potential clinical utility. These mice contain -2 megabases of the human Ig heavy and kappa light chain loci that functionally recapitulate the human humoral immune system. In preliminary studies, we have immunized Xenomice with a number of HIV envelope antigens, including recombinant fusion proteins expressing several of the variable loop domains of the viral surface protein, and a recombinant gpl20 derived from the primary virus isolate, SF162. This latter antigen was uccessful in eliciting Mabs that recognized native viral envelope proteins, including antibodies with potent neutralizing activities for the SF162 strain. Multiple types of epitopes were recognized, including some that had not been previously described. Domains recognized by neutralizing Mabs included the CD4-binding domain and other conserved conformational epitopes in gpl20, as well as sites in the V3 and V1/V2 hypervariable regions. The most potently neutralizing antibodies were directed against type-specific V1/V2 epitopes. In further proposed studies, the epitopes recognized by current neutralizing antibodies will be fully characterized, and the complete range of their neutralizing activities determined. Additional immunizations will be performed with related gpl20 immunogens derived from additional strains, including non-clade B strains. In order to elicit antibodies to native epitopes important for neutralization that may not survive gpl20 purification, immunizations will also be performed with native envelope complexes expressed on virion particles and on mouse B cells expressing the complete e n v gene. Immunizations will also be performed with viral particles expressing the HIV receptors, CD4, CCR5 and CXCR4, on their surfaces, as well as with mixtures of particles expressing both Env and HIV receptors, in order to generate human antibodies against 'activated gpl20' epitopes, or against the receptors themselves. To facilitate the identification of antibodies with functional activities, hybridomas will be screened directly by a sensitive neutralization assay, in addition to traditional binding assays. Epitopes recognized by Mabs with neutralizing activities will be fully mapped, and the full range of antiviral activities of interesting Mabs will be characterized. It is anticipated that these studies should help define the diversity of neutralization epitopes present both on the surface of HIV-1 and its cellular receptors. Ultimately, these studies may lead to the generation of a cocktail of novel human Mabs with antiviral activities against multiple clinical strains, that could serve as an effective immunotherapeutic reagent to control and prevent HIV infection.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI050452-04
Application #
6841627
Study Section
AIDS and Related Research 8 (AARR)
Program Officer
Ahlers, Jeffrey D
Project Start
2002-02-01
Project End
2007-01-31
Budget Start
2005-02-01
Budget End
2006-01-31
Support Year
4
Fiscal Year
2005
Total Cost
$389,000
Indirect Cost
Name
Public Health Research Institute
Department
Type
DUNS #
City
Newark
State
NJ
Country
United States
Zip Code
07103
Zolla-Pazner, Susan; Cohen, Sandra Sharpe; Krachmarov, Chavdar et al. (2008) Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope. Virology 372:233-46
Honnen, W J; Krachmarov, C; Kayman, S C et al. (2007) Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positions fro J Virol 81:1424-32
Burkhart, Michael D; D'Agostino, Paul; Kayman, Samuel C et al. (2005) Involvement of the C-terminal disulfide-bonded loop of murine leukemia virus SU protein in a postbinding step critical for viral entry. J Virol 79:7868-76
Krachmarov, Chavdar; Pinter, Abraham; Honnen, William J et al. (2005) Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking. J Virol 79:780-90
Pinter, Abraham; Honnen, William J; D'Agostino, Paul et al. (2005) The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates. J Virol 79:6909-17
Pinter, Abraham; Honnen, William J; He, Yuxian et al. (2004) The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. J Virol 78:5205-15
He, Yuxian; D'Agostino, Paul; Pinter, Abraham (2003) Analysis of the immunogenic properties of a single-chain polypeptide analogue of the HIV-1 gp120-CD4 complex in transgenic mice that produce human immunoglobulins. Vaccine 21:4421-9
He, Yuxian; Honnen, William J; Krachmarov, Chavdar P et al. (2002) Efficient isolation of novel human monoclonal antibodies with neutralizing activity against HIV-1 from transgenic mice expressing human Ig loci. J Immunol 169:595-605